Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Supriya-Lifescience-Ltd."

5 News Found

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
News | February 09, 2024

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore

Supriya Lifesciences received GMP certification from ANVISA Brazil
News | January 06, 2024

Supriya Lifesciences received GMP certification from ANVISA Brazil

The clearance of this audit marks the successful registration of 8 APIs with CADIFA

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr
News | November 08, 2023

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Supriya Lifescience collaborates with Plasma Nutrition for protein technology
News | August 03, 2023

Supriya Lifescience collaborates with Plasma Nutrition for protein technology

The primary purpose of this collaboration is to bring the optimized protein into the Indian market

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D
People | May 27, 2023

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

Latest Stories

CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo in combination with Cisplatin and Gemcitabine

AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million

Takeda receives positive CHMP opinion for Fruquintinib in previously treated mCRC

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging